0000950170-24-025193.txt : 20240304
0000950170-24-025193.hdr.sgml : 20240304
20240304194135
ACCESSION NUMBER: 0000950170-24-025193
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240229
FILED AS OF DATE: 20240304
DATE AS OF CHANGE: 20240304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rangwala Reshma
CENTRAL INDEX KEY: 0001825322
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36167
FILM NUMBER: 24717667
MAIL ADDRESS:
STREET 1: RIVER OAKS TOWER
STREET 2: 3730 KIRBY DRIVE, SUITE 1200
CITY: HOUSTON
STATE: TX
ZIP: 77098
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc.
CENTRAL INDEX KEY: 0001503802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 263931704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 85 WELLS AVENUE
STREET 2: SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
BUSINESS PHONE: 617-658-0600
MAIL ADDRESS:
STREET 1: 85 WELLS AVENUE
STREET 2: SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
4
1
ownership.xml
4
X0508
4
2024-02-29
0001503802
Karyopharm Therapeutics Inc.
KPTI
0001825322
Rangwala Reshma
C/O KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE
NEWTON
MA
02459
false
true
false
false
EVP & Chief Medical Officer
false
Common
2024-02-29
4
S
false
15667
1.17
D
355689
D
Common
2024-03-01
4
S
false
5969
1.20
D
349720
D
This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person.
/s/Nancy Smith as Attorney-in-Fact for Reshma Rangwala
2024-03-04